Apr 22 |
With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing
|
Apr 22 |
BioCryst to Report First Quarter 2024 Financial Results on May 6
|
Apr 17 |
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
|
Apr 10 |
12 Best Depressed Stocks To Buy in 2024
|
Apr 3 |
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 13 |
13 Best Biotech Stocks To Buy Under $20
|
Mar 1 |
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
|
Feb 28 |
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript
|
Feb 27 |
BioCryst Pharmaceuticals files for a mixed securities shelf
|
Feb 27 |
BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
|